[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 16-year-old with the classic triad of Andersen-Tawil Syndrome (ATS/LQT7): periodic paralysis (muscle weakness), dysmorphic features (low-set ears, micrognathia, clinodactyly), and cardiac abnormalities (prolonged QTc, prominent U waves, ventricular arrhythmias). KCNJ2 mutation confirms the diagnosis. Key discriminating findings: confirmed KCNJ2 mutation, persistent ventricular arrhythmias despite beta-blocker therapy, and the specific syndrome context. Flecainide (Option C) is the keyed answer and is uniquely appropriate because ATS is an exception among LQTS subtypes—flecainide has demonstrated efficacy in suppressing ventricular arrhythmias in KCNJ2-related ATS, unlike other LQTS where Class IC agents are typically avoided. Nadolol (A) has already failed (beta-blocker therapy ongoing). Amiodarone (B) is not first-line for refractory ATS arrhythmias. Mexiletine (D) lacks specific evidence in ATS. Verapamil (E) is inappropriate and potentially harmful in LQTS. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting specialized knowledge of this rare channelopathy. Minimal fix: None needed; item is well-constructed and discriminates appropriately.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 16-year-old with the classic triad of Andersen-Tawil Syndrome (ATS/LQT7): periodic paralysis (muscle weakness), dysmorphic features (low-set ears, micrognathia, clinodactyly), and cardiac abnormalities (prolonged QTc, prominent U waves, ventricular arrhythmias). KCNJ2 mutation confirms the diagnosis. Key discriminating findings: confirmed KCNJ2 mutation, persistent ventricular arrhythmias despite beta-blocker therapy, and the specific syndrome context. Flecainide (Option C) is the keyed answer and is uniquely appropriate because ATS is an exception among LQTS subtypes—flecainide has demonstrated efficacy in suppressing ventricular arrhythmias in KCNJ2-related ATS, unlike other LQTS where Class IC agents are typically avoided. Nadolol (A) has already failed (beta-blocker therapy ongoing). Amiodarone (B) is not first-line for refractory ATS arrhythmias. Mexiletine (D) lacks specific evidence in ATS. Verapamil (E) is inappropriate and potentially harmful in LQTS. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting specialized knowledge of this rare channelopathy. Minimal fix: None needed; item is well-constructed and discriminates appropriately.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 55-year-old man with bone pain, exophthalmos, perinephric infiltration ('hairy kidney'), osteosclerotic lesions, and biopsy showing CD68+/CD1a- foamy histiocytes with BRAF V600E mutation. These findings are pathognomonic for Erdheim-Chester Disease (ECD), a rare non-Langerhans cell histiocytosis. Key discriminating features include: (1) 'hairy kidney' appearance (characteristic perinephric infiltration), (2) osteosclerotic lesions in long bones, (3) CD68+/CD1a- immunophenotype distinguishing it from Langerhans cell histiocytosis, and (4) BRAF V600E mutation present in >50% of ECD cases. Vemurafenib (Option C), a BRAF inhibitor, is the established targeted therapy for BRAF-mutated ECD with superior efficacy compared to traditional immunosuppression. Rituximab (A) targets CD20+ B-cells, irrelevant here. High-dose prednisone (B) may provide symptomatic relief but is inferior to targeted therapy. Methotrexate (D) and infliximab (E) lack specific indication for BRAF-mutated ECD. The stem provides sufficient discriminating details to uniquely identify ECD and select targeted BRAF inhibition. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 55-year-old man with bone pain, exophthalmos, perinephric infiltration ('hairy kidney'), osteosclerotic lesions, and biopsy showing CD68+/CD1a- foamy histiocytes with BRAF V600E mutation. These findings are pathognomonic for Erdheim-Chester Disease (ECD), a rare non-Langerhans cell histiocytosis. Key discriminating features include: (1) 'hairy kidney' appearance (characteristic perinephric infiltration), (2) osteosclerotic lesions in long bones, (3) CD68+/CD1a- immunophenotype distinguishing it from Langerhans cell histiocytosis, and (4) BRAF V600E mutation present in >50% of ECD cases. Vemurafenib (Option C), a BRAF inhibitor, is the established targeted therapy for BRAF-mutated ECD with superior efficacy compared to traditional immunosuppression. Rituximab (A) targets CD20+ B-cells, irrelevant here. High-dose prednisone (B) may provide symptomatic relief but is inferior to targeted therapy. Methotrexate (D) and infliximab (E) lack specific indication for BRAF-mutated ECD. The stem provides sufficient discriminating details to uniquely identify ECD and select targeted BRAF inhibition. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 35-week pregnant woman with AFLP (elevated transaminases, thrombocytopenia, hypoglycemia, coagulopathy) who delivers urgently. Key discriminating findings: maternal AFLP diagnosis and question focus on preventing sudden neonatal death through specific screening. The clinical problem asks which test should be prioritized for the neonate given maternal AFLP. The keyed answer (B: plasma acylcarnitine profile) is correct because maternal AFLP has a well-established association with fetal LCHAD deficiency (a fatty acid oxidation disorder). Affected neonates risk life-threatening hypoketotic hypoglycemia and sudden death if undiagnosed. Acylcarnitine profile detects elevated 3-hydroxy long-chain acylcarnitines diagnostic of LCHAD deficiency, enabling urgent intervention (frequent feeding, avoidance of fasting, carnitine supplementation). Alternative assessments: (A) ammonia/lactate are nonspecific metabolic markers, not diagnostic for LCHAD; (C) tests for galactosemia, unrelated to AFLP; (D) VLCFA screens for peroxisomal disorders like adrenoleukodystrophy, not fatty acid oxidation defects; (E) hemoglobin electrophoresis is irrelevant. No logical flaws: stem provides sufficient context, one clearly superior answer exists, and the key matches. Medical accuracy is excellent, reflecting current understanding of AFLP-LCHAD association. Minimal fix: none needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 35-week pregnant woman with AFLP (elevated transaminases, thrombocytopenia, hypoglycemia, coagulopathy) who delivers urgently. Key discriminating findings: maternal AFLP diagnosis and question focus on preventing sudden neonatal death through specific screening. The clinical problem asks which test should be prioritized for the neonate given maternal AFLP. The keyed answer (B: plasma acylcarnitine profile) is correct because maternal AFLP has a well-established association with fetal LCHAD deficiency (a fatty acid oxidation disorder). Affected neonates risk life-threatening hypoketotic hypoglycemia and sudden death if undiagnosed. Acylcarnitine profile detects elevated 3-hydroxy long-chain acylcarnitines diagnostic of LCHAD deficiency, enabling urgent intervention (frequent feeding, avoidance of fasting, carnitine supplementation). Alternative assessments: (A) ammonia/lactate are nonspecific metabolic markers, not diagnostic for LCHAD; (C) tests for galactosemia, unrelated to AFLP; (D) VLCFA screens for peroxisomal disorders like adrenoleukodystrophy, not fatty acid oxidation defects; (E) hemoglobin electrophoresis is irrelevant. No logical flaws: stem provides sufficient context, one clearly superior answer exists, and the key matches. Medical accuracy is excellent, reflecting current understanding of AFLP-LCHAD association. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes dapsone-induced methemoglobinemia (chocolate-colored blood, 25% MetHb) in a G6PD-deficient patient who deteriorates after methylene blue administration, developing acute hemolysis and worsening hypoxia. Key discriminating findings: (1) G6PD deficiency explicitly stated, (2) methylene blue already failed and caused hemolysis, (3) severe methemoglobinemia (25%) with clinical deterioration. The keyed answer (C: Exchange transfusion) is correct because methylene blue requires G6PD-generated NADPH to function and is contraindicated in G6PD deficiency; repeating it (A) would worsen hemolysis. Ascorbic acid (B) reduces methemoglobin too slowly for life-threatening cases (25% with deterioration). Hyperbaric oxygen (D) does not address methemoglobinemia pathophysiology. Hydroxocobalamin (E) treats cyanide toxicity, not methemoglobinemia. Exchange transfusion rapidly removes both methemoglobin-containing RBCs and circulating dapsone, making it the definitive rescue therapy when methylene blue is contraindicated or has failed. Medical accuracy: The item correctly identifies methylene blue contraindication in G6PD deficiency and appropriate escalation to exchange transfusion for severe refractory methemoglobinemia. No logical flaws; stem provides sufficient detail for unique best answer determination. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes dapsone-induced methemoglobinemia (chocolate-colored blood, 25% MetHb) in a G6PD-deficient patient who deteriorates after methylene blue administration, developing acute hemolysis and worsening hypoxia. Key discriminating findings: (1) G6PD deficiency explicitly stated, (2) methylene blue already failed and caused hemolysis, (3) severe methemoglobinemia (25%) with clinical deterioration. The keyed answer (C: Exchange transfusion) is correct because methylene blue requires G6PD-generated NADPH to function and is contraindicated in G6PD deficiency; repeating it (A) would worsen hemolysis. Ascorbic acid (B) reduces methemoglobin too slowly for life-threatening cases (25% with deterioration). Hyperbaric oxygen (D) does not address methemoglobinemia pathophysiology. Hydroxocobalamin (E) treats cyanide toxicity, not methemoglobinemia. Exchange transfusion rapidly removes both methemoglobin-containing RBCs and circulating dapsone, making it the definitive rescue therapy when methylene blue is contraindicated or has failed. Medical accuracy: The item correctly identifies methylene blue contraindication in G6PD deficiency and appropriate escalation to exchange transfusion for severe refractory methemoglobinemia. No logical flaws; stem provides sufficient detail for unique best answer determination. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 3-month-old with erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absent B cells, and oligoclonal activated T cells—a classic presentation of Omenn syndrome. Key discriminating findings are: (1) absent B cells with (2) oligoclonal activated T cells, (3) erythroderma, and (4) eosinophilia in an infant. Hypomorphic RAG1/RAG2 mutations (Option B) cause partial V(D)J recombination, producing oligoclonal autoreactive T cells without functional B cells—the pathognomonic immunophenotype of Omenn syndrome. Option A (BTK) causes X-linked agammaglobulinemia with absent B cells but normal T cells, not activated oligoclonal T cells. Option C (CD40L) causes hyper-IgM syndrome with normal/elevated B cells. Option D (STAT3) causes hyper-IgE syndrome (Job syndrome) with eczema and elevated IgE but normal B-cell numbers and polyclonal T cells. Option E (WAS) causes Wiskott-Aldrich syndrome with thrombocytopenia (not mentioned) and typically normal B-cell numbers. The stem provides sufficient discriminating features; the keyed answer is medically accurate and uniquely defensible. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 3-month-old with erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absent B cells, and oligoclonal activated T cells—a classic presentation of Omenn syndrome. Key discriminating findings are: (1) absent B cells with (2) oligoclonal activated T cells, (3) erythroderma, and (4) eosinophilia in an infant. Hypomorphic RAG1/RAG2 mutations (Option B) cause partial V(D)J recombination, producing oligoclonal autoreactive T cells without functional B cells—the pathognomonic immunophenotype of Omenn syndrome. Option A (BTK) causes X-linked agammaglobulinemia with absent B cells but normal T cells, not activated oligoclonal T cells. Option C (CD40L) causes hyper-IgM syndrome with normal/elevated B cells. Option D (STAT3) causes hyper-IgE syndrome (Job syndrome) with eczema and elevated IgE but normal B-cell numbers and polyclonal T cells. Option E (WAS) causes Wiskott-Aldrich syndrome with thrombocytopenia (not mentioned) and typically normal B-cell numbers. The stem provides sufficient discriminating features; the keyed answer is medically accurate and uniquely defensible. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 4-month-old with classic ALCAPA presentation: failure to thrive, diaphoresis during feeding (anginal equivalent), deep Q waves in lateral leads (anterolateral infarction pattern), and dilated left ventricle (ischemic cardiomyopathy). The question asks for the diagnostic Doppler flow pattern. Key pathophysiology: after neonatal period, pulmonary vascular resistance drops, creating a pressure gradient where aortic blood flows via RCA→collaterals→LCA→retrograde into low-pressure pulmonary artery (coronary steal phenomenon). Option C correctly identifies this pathognomonic retrograde flow from LCA into PA. Option A describes normal coronary flow. Option B is physiologically implausible (antegrade flow from PA would require higher PA pressure). Option D describes PDA flow, not coronary pathology. Option E suggests stenosis, not ALCAPA. The keyed answer is medically accurate and uniquely defensible. No logical flaws exist; stem provides sufficient discriminating features. Medical accuracy: fully consistent with pediatric cardiology standards and echocardiographic diagnosis of ALCAPA. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 4-month-old with classic ALCAPA presentation: failure to thrive, diaphoresis during feeding (anginal equivalent), deep Q waves in lateral leads (anterolateral infarction pattern), and dilated left ventricle (ischemic cardiomyopathy). The question asks for the diagnostic Doppler flow pattern. Key pathophysiology: after neonatal period, pulmonary vascular resistance drops, creating a pressure gradient where aortic blood flows via RCA→collaterals→LCA→retrograde into low-pressure pulmonary artery (coronary steal phenomenon). Option C correctly identifies this pathognomonic retrograde flow from LCA into PA. Option A describes normal coronary flow. Option B is physiologically implausible (antegrade flow from PA would require higher PA pressure). Option D describes PDA flow, not coronary pathology. Option E suggests stenosis, not ALCAPA. The keyed answer is medically accurate and uniquely defensible. No logical flaws exist; stem provides sufficient discriminating features. Medical accuracy: fully consistent with pediatric cardiology standards and echocardiographic diagnosis of ALCAPA. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 60-year-old male with nephrotic syndrome, low C3/normal C4, C3-dominant IF staining, MPGN pattern, negative SPEP but abnormal FLC ratio (5.0, elevated kappa). The vignette describes C3 glomerulopathy with monoclonal gammopathy. However, the critical issue is that an abnormal kappa:lambda ratio alone (5.0) with negative SPEP does not definitively establish MGRS requiring clone-directed chemotherapy. MGRS diagnosis requires demonstrating that the monoclonal protein is pathogenic and causing kidney disease. The FLC ratio of 5.0, while abnormal (normal ~0.26-1.65), could represent MGUS or early myeloma without direct renal pathogenicity. C3G can be primary (alternative pathway dysregulation) or secondary to MGRS. Without additional evidence (bone marrow findings, higher FLC levels, or proven pathogenic monoclonal protein), eculizumab (Option A) - a complement C5 inhibitor - is the established first-line treatment for primary C3G. Clone-directed therapy is reserved for proven MGRS. The stem is underspecified regarding whether this is definitively MGRS versus primary C3G with incidental paraprotein. Minimal fix: Add 'Bone marrow biopsy shows 15% clonal plasma cells' to definitively establish MGRS warranting clone-directed therapy.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. Key stem clues: 60-year-old male with nephrotic syndrome, low C3/normal C4, C3-dominant IF staining, MPGN pattern, negative SPEP but abnormal FLC ratio (5.0, elevated kappa). The vignette describes C3 glomerulopathy with monoclonal gammopathy. However, the critical issue is that an abnormal kappa:lambda ratio alone (5.0) with negative SPEP does not definitively establish MGRS requiring clone-directed chemotherapy. MGRS diagnosis requires demonstrating that the monoclonal protein is pathogenic and causing kidney disease. The FLC ratio of 5.0, while abnormal (normal ~0.26-1.65), could represent MGUS or early myeloma without direct renal pathogenicity. C3G can be primary (alternative pathway dysregulation) or secondary to MGRS. Without additional evidence (bone marrow findings, higher FLC levels, or proven pathogenic monoclonal protein), eculizumab (Option A) - a complement C5 inhibitor - is the established first-line treatment for primary C3G. Clone-directed therapy is reserved for proven MGRS. The stem is underspecified regarding whether this is definitively MGRS versus primary C3G with incidental paraprotein. Minimal fix: Add 'Bone marrow biopsy shows 15% clonal plasma cells' to definitively establish MGRS warranting clone-directed therapy.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - Option A is the correct best answer. The stem describes a time-triggered mandatory breath followed by a diaphragmatic contraction during the inspiratory phase that triggers a second breath during exhalation (breath stacking). This sequence is classic double triggering due to insufficient inspiratory time or flow (flow starvation). The patient's inspiratory effort continues beyond the ventilator's inspiratory time, triggering a second breath before exhalation completes. Key discriminating findings: (1) time-triggered first breath, (2) diaphragmatic contraction during inspiratory phase, (3) second breath triggered during exhalation, (4) breath stacking. Reverse triggering (Option B, the keyed answer) describes ventilator-induced diaphragmatic contraction where passive insufflation reflexively triggers patient effort - the opposite temporal sequence. In reverse triggering, the ventilator breath comes first and induces the patient effort; here, the patient effort during the mandatory breath's inspiratory phase triggers the second breath. The stem explicitly states the esophageal pressure drop (patient effort) occurs during the inspiratory phase and triggers the subsequent breath - this is flow starvation causing double triggering, not reverse triggering. Minimal fix: Change the key from B to A, or rewrite the stem to describe ventilator breath inducing subsequent patient effort (true reverse triggering).\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - Option A is the correct best answer. The stem describes a time-triggered mandatory breath followed by a diaphragmatic contraction during the inspiratory phase that triggers a second breath during exhalation (breath stacking). This sequence is classic double triggering due to insufficient inspiratory time or flow (flow starvation). The patient's inspiratory effort continues beyond the ventilator's inspiratory time, triggering a second breath before exhalation completes. Key discriminating findings: (1) time-triggered first breath, (2) diaphragmatic contraction during inspiratory phase, (3) second breath triggered during exhalation, (4) breath stacking. Reverse triggering (Option B, the keyed answer) describes ventilator-induced diaphragmatic contraction where passive insufflation reflexively triggers patient effort - the opposite temporal sequence. In reverse triggering, the ventilator breath comes first and induces the patient effort; here, the patient effort during the mandatory breath's inspiratory phase triggers the second breath. The stem explicitly states the esophageal pressure drop (patient effort) occurs during the inspiratory phase and triggers the subsequent breath - this is flow starvation causing double triggering, not reverse triggering. Minimal fix: Change the key from B to A, or rewrite the stem to describe ventilator breath inducing subsequent patient effort (true reverse triggering).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists than the keyed option. Key stem clues: 28-year-old postpartum woman with isolated aPTT prolongation (78s), normal PT, mixing study non-correction, and Factor VIII <1% indicates acquired hemophilia A with inhibitor. The clinical problem is acute bleeding control in acquired hemophilia A with high-titer inhibitor. The keyed answer (D: Recombinant Porcine Factor VIII) is a reasonable option with low cross-reactivity to human anti-FVIII antibodies. However, Option C (Recombinant Human Factor VIII) is NOT listed among the choices as a standalone bypassing agent option. The rationale correctly states that bypassing agents (rFVIIa or FEIBA) are first-line, but neither appears explicitly in the options. Recombinant porcine FVIII is appropriate but is typically considered when bypassing agents fail or are unavailable. The item is miskeyed because in current practice, bypassing agents (rFVIIa/FEIBA) are true first-line for acute bleeding in acquired hemophilia A with inhibitors, not porcine FVIII. Since bypassing agents aren't offered, the item forces selection of a second-line agent as 'first-line.' Minimal fix: Add 'Recombinant Factor VIIa' or 'FEIBA' as an option and key it, or reframe the question to ask for therapy when bypassing agents are unavailable.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists than the keyed option. Key stem clues: 28-year-old postpartum woman with isolated aPTT prolongation (78s), normal PT, mixing study non-correction, and Factor VIII <1% indicates acquired hemophilia A with inhibitor. The clinical problem is acute bleeding control in acquired hemophilia A with high-titer inhibitor. The keyed answer (D: Recombinant Porcine Factor VIII) is a reasonable option with low cross-reactivity to human anti-FVIII antibodies. However, Option C (Recombinant Human Factor VIII) is NOT listed among the choices as a standalone bypassing agent option. The rationale correctly states that bypassing agents (rFVIIa or FEIBA) are first-line, but neither appears explicitly in the options. Recombinant porcine FVIII is appropriate but is typically considered when bypassing agents fail or are unavailable. The item is miskeyed because in current practice, bypassing agents (rFVIIa/FEIBA) are true first-line for acute bleeding in acquired hemophilia A with inhibitors, not porcine FVIII. Since bypassing agents aren't offered, the item forces selection of a second-line agent as 'first-line.' Minimal fix: Add 'Recombinant Factor VIIa' or 'FEIBA' as an option and key it, or reframe the question to ask for therapy when bypassing agents are unavailable.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a traveler from Malaysian Borneo with high-grade fevers, severe thrombocytopenia, high parasitemia, and 'band form' trophozoites resembling P. malariae but with P. falciparum-like severity. These clues point to Plasmodium knowlesi, a zoonotic malaria endemic to Southeast Asia (particularly Malaysian Borneo). The question asks what distinguishes this pathogen's replication cycle from P. falciparum. Key discriminating findings: geographic origin (Malaysian Borneo), band forms (characteristic of P. knowlesi/malariae), high parasitemia with severe disease (atypical for P. malariae), and clinical severity. P. knowlesi's defining feature is its 24-hour erythrocytic cycle (quotidian fever), which allows rapid parasite multiplication and severe disease. Option A (24-hour cycle) is correct. Option B (48-hour) describes P. falciparum, vivax, and ovale. Option C (72-hour) describes P. malariae. Option D (hypnozoite stage) applies to P. vivax/ovale only. Option E (reticulocyte preference) is characteristic of P. vivax. The stem provides sufficient clues for a unique best answer. Medical accuracy: fully consistent with current knowledge of P. knowlesi. No fix needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a traveler from Malaysian Borneo with high-grade fevers, severe thrombocytopenia, high parasitemia, and 'band form' trophozoites resembling P. malariae but with P. falciparum-like severity. These clues point to Plasmodium knowlesi, a zoonotic malaria endemic to Southeast Asia (particularly Malaysian Borneo). The question asks what distinguishes this pathogen's replication cycle from P. falciparum. Key discriminating findings: geographic origin (Malaysian Borneo), band forms (characteristic of P. knowlesi/malariae), high parasitemia with severe disease (atypical for P. malariae), and clinical severity. P. knowlesi's defining feature is its 24-hour erythrocytic cycle (quotidian fever), which allows rapid parasite multiplication and severe disease. Option A (24-hour cycle) is correct. Option B (48-hour) describes P. falciparum, vivax, and ovale. Option C (72-hour) describes P. malariae. Option D (hypnozoite stage) applies to P. vivax/ovale only. Option E (reticulocyte preference) is characteristic of P. vivax. The stem provides sufficient clues for a unique best answer. Medical accuracy: fully consistent with current knowledge of P. knowlesi. No fix needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]